Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Aurobindo On Easier US Biosimilar Pathway, Zentiva Miss And Deal Strategy

Nov 11 2025

• By Vibha Ravi

Aurobindo Pharma on US biosimilar regulatory changes, Europe deal strategy — Aurobindo Pharma on US biosimilar regulatory changes, Europe deal strategy (Shutterstock)

Related Content

Does Lupin’s Proposed US Site Spell The Beginning Of An Indian Wave?

Oct 09 2025

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

Aug 06 2025

Aurobindo: US Tariffs ‘Not A Challenge’ For Now, Scouting For Biosimilars Tie-Ups

Feb 14 2025

Related Companies

Aurobindo Pharma USA Inc.

Aurobindo Pharma Limited

Additional Topics

Strategy Sales & Earnings Regulation Biosimilars Deals Clinical Trials AAM

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window